Short Interest in OpGen, Inc. (NASDAQ:OPGN) Declines By 17.5%

OpGen, Inc. (NASDAQ:OPGN) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 30,700 shares, a decline of 17.5% from the May 31st total of 37,200 shares. Approximately 2.4% of the company’s shares are short sold. Based on an average daily trading volume, of 175,600 shares, the short-interest ratio is presently 0.2 days.

OpGen Trading Up 2.0 %

Shares of NASDAQ OPGN traded up $0.05 during mid-day trading on Friday, reaching $2.58. The company had a trading volume of 4,957 shares, compared to its average volume of 24,590. OpGen has a 52 week low of $1.65 and a 52 week high of $38.40. The business’s 50-day moving average is $3.66 and its 200-day moving average is $4.37. The stock has a market cap of $3.46 million, a price-to-earnings ratio of -0.04 and a beta of -0.65.

Institutional Trading of OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp acquired a new position in OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent SEC filing. Institutional investors own 2.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on OpGen in a research report on Saturday, May 25th. They issued a “sell” rating on the stock.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.